APGE
Apogee Therapeutics, Inc.
Key Financials
Operating Income
$-285595000
↓ 31.7%
Net Income
$-255843000
↓ 40.5%
EPS (Diluted)
$-4.22
↓ 27.9%
Total Assets
$937.1M
↑ 24.3%
Total Liabilities
$33.3M
↓ 10.5%
Cash & Equivalents
$131.5M
↓ 7.2%
Operating Cash Flow
$-227450000.00
↓ 32.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 5/15/2026 | View on SEC |
| 144 | 5/13/2026 | View on SEC |
| 10-Q | 5/11/2026 | View on SEC |
| 8-K | 5/11/2026 | View on SEC |
| 4 | 5/8/2026 | View on SEC |
| 144 | 5/6/2026 | View on SEC |
| 4 | 5/4/2026 | View on SEC |
| 144 | 5/1/2026 | View on SEC |
| DEFA14A | 4/24/2026 | View on SEC |
| ARS | 4/24/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | APGE |
| Company Name | Apogee Therapeutics, Inc. |
| CIK | 1974640 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | 650-394-5230 |